RxDoctor Payments Data

Anna Stouffer

Psychiatric/Mental Health · Wesley Chapel, FLNPI 1225432651

Payments from drug & device makers

$919in general payments, 2019–2025

Across 37 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477
  • Axsome Therapeutics, Inc.$122
  • Vanda Pharmaceuticals Inc.$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • Alkermes, Inc.$47
  • plus $79 from 2 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$919 in reported general payments places this provider in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$11,723
Medicare patients
15
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$83,369
VraylarCariprazine Hcl13$18,814
Bupropion XlBupropion Hcl49$5,666
Aripiprazole41$3,114
Oxcarbazepine16$1,782
Duloxetine Hcl27$1,059
Buspirone Hcl72$1,056
Doxepin Hcl16$974
Clonazepam55$618
Prazosin Hcl19$558
Lamotrigine57$537
Quetiapine Fumarate ErQuetiapine Fumarate25$526
Venlafaxine Hcl ErVenlafaxine Hcl57$521
Trazodone Hcl60$422
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$477$18,81413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →